• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人纤溶酶原催化结构域在激活后会发生异常的构象变化。

Human plasminogen catalytic domain undergoes an unusual conformational change upon activation.

作者信息

Wang X, Terzyan S, Tang J, Loy J A, Lin X, Zhang X C

机构信息

Oklahoma Medical Research Foundation, Crystallography Program, 825 N. E. 13(th) Street, Oklahoma City, OK, 73104, USA.

出版信息

J Mol Biol. 2000 Jan 28;295(4):903-14. doi: 10.1006/jmbi.1999.3397.

DOI:10.1006/jmbi.1999.3397
PMID:10656799
Abstract

Activation of the serine protease plasmin from its zymogen, plasminogen, is the key step in fibrinolysis leading to blood clot dissolution. It also plays critical roles in cell migration, such as in tumor metastasis. Here, we report the crystal structure of an inactive S741A mutant of human plasminogen catalytic domain at 2.0 A resolution. This structure permits a direct comparison with that of the plasmin catalytic unit. Unique conformational differences are present between these two structures that are not seen in other zymogen-enzyme pairs of the trypsin family. The functional significance of these differences and the structural basis of plasminogen activation is discussed in the light of this new structure.

摘要

丝氨酸蛋白酶纤溶酶从其酶原纤溶酶原的激活是导致血凝块溶解的纤维蛋白溶解的关键步骤。它在细胞迁移中也起着关键作用,例如在肿瘤转移中。在这里,我们报告了人纤溶酶原催化结构域的无活性S741A突变体在2.0埃分辨率下的晶体结构。该结构允许与纤溶酶催化单元的结构进行直接比较。这两种结构之间存在独特的构象差异,而在胰蛋白酶家族的其他酶原-酶对中未见这种差异。根据这一新结构讨论了这些差异的功能意义和纤溶酶原激活的结构基础。

相似文献

1
Human plasminogen catalytic domain undergoes an unusual conformational change upon activation.人纤溶酶原催化结构域在激活后会发生异常的构象变化。
J Mol Biol. 2000 Jan 28;295(4):903-14. doi: 10.1006/jmbi.1999.3397.
2
Characterization of Lys-698-to-Met substitution in human plasminogen catalytic domain.人纤溶酶原催化结构域中赖氨酸698到甲硫氨酸取代的表征
Proteins. 2004 Aug 1;56(2):277-84. doi: 10.1002/prot.20070.
3
Crystal structure of the proenzyme domain of plasminogen.纤溶酶原酶原结构域的晶体结构。
Biochemistry. 1999 Aug 24;38(34):11180-8. doi: 10.1021/bi991130r.
4
The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator.重组双链人组织型纤溶酶原激活剂催化结构域的2.3埃晶体结构。
J Mol Biol. 1996 Apr 26;258(1):117-35. doi: 10.1006/jmbi.1996.0238.
5
Function of the central domain of streptokinase in substrate plasminogen docking and processing revealed by site-directed mutagenesis.通过定点诱变揭示链激酶中心结构域在底物纤溶酶原对接和加工中的功能。
Protein Sci. 1999 Dec;8(12):2791-805. doi: 10.1110/ps.8.12.2791.
6
Plasminogen: a structural review.纤溶酶原:结构综述。
Blood Coagul Fibrinolysis. 1992 Oct;3(5):605-14.
7
Structure and binding determinants of the recombinant kringle-2 domain of human plasminogen to an internal peptide from a group A Streptococcal surface protein.人纤溶酶原重组kringle-2结构域与A组链球菌表面蛋白内部肽段的结构及结合决定因素
J Mol Biol. 2001 May 11;308(4):705-19. doi: 10.1006/jmbi.2001.4646.
8
Arginine 719 in human plasminogen mediates formation of the staphylokinase:plasmin activator complex.人纤溶酶原中的精氨酸719介导葡萄球菌激酶:纤溶酶激活剂复合物的形成。
Biochemistry. 1998 May 5;37(18):6380-6. doi: 10.1021/bi972807i.
9
Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution.分辨率为2.1埃的人金属蛋白酶组织抑制剂-2的三维结构
J Mol Biol. 1998 Dec 11;284(4):1133-40. doi: 10.1006/jmbi.1998.2223.
10
Crystal structure of an activation intermediate of cathepsin E.组织蛋白酶E激活中间体的晶体结构
J Mol Biol. 2004 Sep 17;342(3):889-99. doi: 10.1016/j.jmb.2004.07.073.

引用本文的文献

1
Assessment of clot-lysing and membrane-stabilizing capacity of ascorbic acid: approach with molecular docking.抗坏血酸的溶栓和膜稳定能力评估:分子对接方法
Toxicol Rep. 2024 Nov 26;13:101831. doi: 10.1016/j.toxrep.2024.101831. eCollection 2024 Dec.
2
A network pharmacology and molecular docking approach in the exploratory investigation of the biological mechanisms of lagundi (Vitex negundo L.) compounds against COVID-19.一种基于网络药理学和分子对接方法对荜澄茄(牡荆)化合物抗 COVID-19 生物学机制的探索性研究
Genomics Inform. 2023 Mar;21(1):e4. doi: 10.5808/gi.22060. Epub 2023 Mar 31.
3
Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease.
鉴定 SARS-CoV-2 主要蛋白酶的宿主细胞蛋白底物。
Int J Mol Sci. 2020 Dec 15;21(24):9523. doi: 10.3390/ijms21249523.
4
Multi-omic studies on missense PLG variants in families with otitis media.多组学研究家族性中耳炎中错义 PLG 变体。
Sci Rep. 2020 Sep 14;10(1):15035. doi: 10.1038/s41598-020-70498-w.
5
Selection of mutant µplasmin for amyloid-β cleavage in vivo.体内突变 µ 型纤溶酶原对淀粉样 β 肽的切割选择。
Sci Rep. 2020 Jul 21;10(1):12117. doi: 10.1038/s41598-020-69079-8.
6
Site-specific PEGylation of micro-plasmin for improved thrombolytic therapy through engineering enhanced resistance against serpin mediated inhibition.通过工程改造增强对丝氨酸蛋白酶抑制剂介导抑制的抗性,实现微纤溶酶的位点特异性聚乙二醇化,以改善溶栓治疗。
PLoS One. 2019 May 29;14(5):e0217234. doi: 10.1371/journal.pone.0217234. eCollection 2019.
7
In vitro fibrinolysis and antithrombosis characterizations of novel recombinant microplasminogen with RGD and GPRP peptides.新型含RGD和GPRP肽的重组微纤溶酶原的体外纤维蛋白溶解和抗血栓形成特性
J Thromb Thrombolysis. 2016 Jul;42(1):118-26. doi: 10.1007/s11239-016-1334-7.
8
Photonic activation of plasminogen induced by low dose UVB.低剂量紫外线B诱导的纤溶酶原的光子激活
PLoS One. 2015 Jan 30;10(1):e0116737. doi: 10.1371/journal.pone.0116737. eCollection 2015.
9
Purification and characterization of mutant miniPlasmin for thrombolytic therapy.突变型 miniPlasmin 的纯化与表征及其在溶栓治疗中的应用。
Thromb J. 2013 Jan 30;11(1):2. doi: 10.1186/1477-9560-11-2.
10
The structure of human microplasmin in complex with textilinin-1, an aprotinin-like inhibitor from the Australian brown snake.人微纤溶酶与 textilinin-1 的复合物结构,textilinin-1 是一种来自澳大利亚棕色蛇的 aprotinin 样抑制剂。
PLoS One. 2013;8(1):e54104. doi: 10.1371/journal.pone.0054104. Epub 2013 Jan 15.